A clinical grade poly I

C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro

H. Navabi, B. Jasani, A. Reece, A. Clayton, Z. Tabi, C. Donninger, M. Mason, M. Adams

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Maturation of dendritic cells (DC) can be triggered in vitro by inflammatory cytokines or Toll-like receptor (TLR) ligands such as CpG or polyI:C. Corresponding, well-characterized agents which can be applied in clinical settings are sparse. We have evaluated a clinical grade, non-toxic analogue of polyI:C, poly(I:C12U) (Ampligen®), as a potential adjuvant for cancer immunotherapy, for its ability to drive maturation of human myeloid DC. Our results provide evidence that poly(I:C12U) is effective in inducing optimal phenotypic (elevated levels of MHC-Class I/Class II, CD83, CCR7, CD86 and CD40 molecules) and functional maturation of human DC in vitro, capable of promoting the production of the inflammatory (Th1-type) cytokine IL-12, with significantly lower levels of IL-10 production, compared to that induced by the parent compound polyI:C. Importantly, poly(I:C12U) has a comparable effect on the maturation and function of DC derived either from healthy donors or cancer patients indicating that it is able to overcome any immune suppressive factors associated with the tumour bearing state. These characteristics make poly(I:C12U) a suitable agent for use as an adjuvant in cancer directed immunotherapeutic regimes.

Original languageEnglish
Pages (from-to)107-115
Number of pages9
JournalVaccine
Volume27
Issue number1
DOIs
Publication statusPublished - Jan 1 2009
Externally publishedYes

Fingerprint

polyinosinic-polycytidylic acid
Poly I-C
Th1 Cells
dendritic cells
Dendritic Cells
T-lymphocytes
Poly I
Tissue Donors
T-Lymphocytes
neoplasms
adjuvants
Neoplasms
cytokines
Cytokines
Toll-Like Receptors
immunotherapy
interleukin-12
Immunologic Factors
Myeloid Cells
Interleukin-12

Keywords

  • Dendritic cell
  • Immunotherapy
  • Maturation
  • Poly (I:CU)

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

A clinical grade poly I : C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. / Navabi, H.; Jasani, B.; Reece, A.; Clayton, A.; Tabi, Z.; Donninger, C.; Mason, M.; Adams, M.

In: Vaccine, Vol. 27, No. 1, 01.01.2009, p. 107-115.

Research output: Contribution to journalArticle

Navabi, H. ; Jasani, B. ; Reece, A. ; Clayton, A. ; Tabi, Z. ; Donninger, C. ; Mason, M. ; Adams, M. / A clinical grade poly I : C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. In: Vaccine. 2009 ; Vol. 27, No. 1. pp. 107-115.
@article{c0a5027be5b6404dbc820fbbeddfbd0e,
title = "A clinical grade poly I: C-analogue (Ampligen{\circledR}) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro",
abstract = "Maturation of dendritic cells (DC) can be triggered in vitro by inflammatory cytokines or Toll-like receptor (TLR) ligands such as CpG or polyI:C. Corresponding, well-characterized agents which can be applied in clinical settings are sparse. We have evaluated a clinical grade, non-toxic analogue of polyI:C, poly(I:C12U) (Ampligen{\circledR}), as a potential adjuvant for cancer immunotherapy, for its ability to drive maturation of human myeloid DC. Our results provide evidence that poly(I:C12U) is effective in inducing optimal phenotypic (elevated levels of MHC-Class I/Class II, CD83, CCR7, CD86 and CD40 molecules) and functional maturation of human DC in vitro, capable of promoting the production of the inflammatory (Th1-type) cytokine IL-12, with significantly lower levels of IL-10 production, compared to that induced by the parent compound polyI:C. Importantly, poly(I:C12U) has a comparable effect on the maturation and function of DC derived either from healthy donors or cancer patients indicating that it is able to overcome any immune suppressive factors associated with the tumour bearing state. These characteristics make poly(I:C12U) a suitable agent for use as an adjuvant in cancer directed immunotherapeutic regimes.",
keywords = "Dendritic cell, Immunotherapy, Maturation, Poly (I:CU)",
author = "H. Navabi and B. Jasani and A. Reece and A. Clayton and Z. Tabi and C. Donninger and M. Mason and M. Adams",
year = "2009",
month = "1",
day = "1",
doi = "10.1016/j.vaccine.2008.10.024",
language = "English",
volume = "27",
pages = "107--115",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - A clinical grade poly I

T2 - C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro

AU - Navabi, H.

AU - Jasani, B.

AU - Reece, A.

AU - Clayton, A.

AU - Tabi, Z.

AU - Donninger, C.

AU - Mason, M.

AU - Adams, M.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Maturation of dendritic cells (DC) can be triggered in vitro by inflammatory cytokines or Toll-like receptor (TLR) ligands such as CpG or polyI:C. Corresponding, well-characterized agents which can be applied in clinical settings are sparse. We have evaluated a clinical grade, non-toxic analogue of polyI:C, poly(I:C12U) (Ampligen®), as a potential adjuvant for cancer immunotherapy, for its ability to drive maturation of human myeloid DC. Our results provide evidence that poly(I:C12U) is effective in inducing optimal phenotypic (elevated levels of MHC-Class I/Class II, CD83, CCR7, CD86 and CD40 molecules) and functional maturation of human DC in vitro, capable of promoting the production of the inflammatory (Th1-type) cytokine IL-12, with significantly lower levels of IL-10 production, compared to that induced by the parent compound polyI:C. Importantly, poly(I:C12U) has a comparable effect on the maturation and function of DC derived either from healthy donors or cancer patients indicating that it is able to overcome any immune suppressive factors associated with the tumour bearing state. These characteristics make poly(I:C12U) a suitable agent for use as an adjuvant in cancer directed immunotherapeutic regimes.

AB - Maturation of dendritic cells (DC) can be triggered in vitro by inflammatory cytokines or Toll-like receptor (TLR) ligands such as CpG or polyI:C. Corresponding, well-characterized agents which can be applied in clinical settings are sparse. We have evaluated a clinical grade, non-toxic analogue of polyI:C, poly(I:C12U) (Ampligen®), as a potential adjuvant for cancer immunotherapy, for its ability to drive maturation of human myeloid DC. Our results provide evidence that poly(I:C12U) is effective in inducing optimal phenotypic (elevated levels of MHC-Class I/Class II, CD83, CCR7, CD86 and CD40 molecules) and functional maturation of human DC in vitro, capable of promoting the production of the inflammatory (Th1-type) cytokine IL-12, with significantly lower levels of IL-10 production, compared to that induced by the parent compound polyI:C. Importantly, poly(I:C12U) has a comparable effect on the maturation and function of DC derived either from healthy donors or cancer patients indicating that it is able to overcome any immune suppressive factors associated with the tumour bearing state. These characteristics make poly(I:C12U) a suitable agent for use as an adjuvant in cancer directed immunotherapeutic regimes.

KW - Dendritic cell

KW - Immunotherapy

KW - Maturation

KW - Poly (I:CU)

UR - http://www.scopus.com/inward/record.url?scp=56949108633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56949108633&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.10.024

DO - 10.1016/j.vaccine.2008.10.024

M3 - Article

VL - 27

SP - 107

EP - 115

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 1

ER -